GLP-1 drugs linked to reduced risk of epilepsy
A retrospective analysis of data from adults treated for type-2 diabetes indicates that glucose-lowering GLP-1 drugs could be linked to a lower risk of epilepsy. The findings appeared… read more.
A retrospective analysis of data from adults treated for type-2 diabetes indicates that glucose-lowering GLP-1 drugs could be linked to a lower risk of epilepsy. The findings appeared… read more.
Lundbeck A/S (Lundbeck) announced that new pipeline data regarding bexicaserin (LP352), a novel investigational drug for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs), will… read more.
A new clinical trial co-led by researchers at FutureNeuro and RCSI University of Medicine and Health Sciences is investigating how advanced brain monitoring could improve the diagnosis and… read more.
Despite evidence of the risk of malformations at birth, or birth defects, use of some antiseizure drugs during pregnancy has persisted, according to a study published on July… read more.
An international research team from the fields of veterinary medicine and genetics has developed a new survey tool to advance canine epilepsy diagnosis and research. Epilepsy and dyskinesia… read more.
NICE(UK): Cenobamate is recommended as an option as an add-on treatment for focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has… read more.
Certain common genetic changes might make some people with focal epilepsy less responsive to seizure medications, finds a new global study led by researchers at UCL and UTHealth… read more.
A new international study has unveiled critical insights in understanding post-traumatic epilepsy (PTE), a condition that can develop following traumatic brain injury. Led by researchers at FutureNeuro, the… read more.
Children of mothers who took certain antiseizure medications while pregnant do not have worse neurodevelopmental outcomes at age 6, according to a long-running study funded by the National… read more.
UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets…. read more.
Targeted blood tests, asking patients about risk factors, and dose modifications can lessen the risk of potentially fatal reactions to antiseizure medications that millions of Americans take for… read more.
New recommendations released in Epileptic Disorders by a global expert group comprising epileptologists, neurologists and pharmacologists from Europe and North America address the critical unmet needs associated with… read more.